Type 1 Diabetes

UF Health provides revolutionary Type 1 diabetes basic science, translational research and patient care. Because our pediatric endocrinologists work hand-in-hand with our basic science colleagues and collaborate with other researchers throughout the nation, we can push the boundaries of diabetes care and achieve success doing it.

 UF Health’s innovative discoveries about Type 1 diabetes

  • Using autoantibody markers to protect individuals at increased risk of Type 1 diabetes
  • Identifying genes associated with genetic susceptibility
  • Defining the physiology of the immune response in Type 1 diabetes
  • Identifying agents suitable for the prevention and reversal of Type 1 diabetes
  • Using innovative media and technology programs to improve diabetes education

What makes our program unique?

  • Being ranked the No. 1-funded institution globally by the Juvenile Diabetes Research Foundation
  • Running the exceptional Florida’s Diabetes Camps each summer at Camp Winona
  • Delivering care via telemedicine appointments; often times this is done directly to a patient’s home
  • Having transition programs for emerging adults with diabetes in collaboration with our adult endocrinology team
  • Using innovation technology, such as advanced pump techniques, continuous glucose sensors and artificial pancreas access
  • Being able to rely on the expertise of Janet Silverstein, MD, a UF Health pediatric endocrinologist, who is also the chair of the Governor’s Diabetes Advisory Council

Studies and Grants

  • TEDDY
    UF Health is participating in the NIH-funded study called The Environmental Determinants of Diabetes in Youth, or TEDDY. We are one of four centers internationally that are part of this study looking for the causes of Type 1 diabetes. There are 8,500 children enrolled in the study, and we expect that some of the children will develop antibodies to Type 1 diabetes and some will develop Type 1 diabetes. We hope that the information collected in the study will give us a pathway going forward to determine the causes of the disease.
  • nPod
    Led by a large team at UF, including the director of the UF Diabetes Institute, Mark Atkinson, PhD, the nPod study allows us to do rapid screens of antibodies for those who passed away from Type 1 diabetes. By studying deceased organs, it will help us identify consistencies among those who suffered from the disease.
  • Medtronic 690G
    UF is one of four sites that have been selected to participate in the Medtronic 690G artificial pancreas study for patients with Type 1 diabetes. The 690G is the next generation artificial pancreas.
  • TrialNet
    This NIH-funded study is a multicenter collaborative that does new onset Type 1 diabetes studies in hopes of eventually preventing the disease. Each year, we screen approximately 25,000 families to determine if their children have the same high-risk antibodies for Type 1 diabetes with the idea of putting those children into prevention studies.
  • Project Endo Echo grant for Type 1 diabetes
    Our pediatric endocrinology division was recently awarded a $1.6 million grant from the Healthy Trust to help improve care for Americans living with diabetes. The concept is to train and support clinicians and their teams to provide access to care for patients in rural and underserved areas, where there is a shortage of pediatric endocrinologists. It is a way to teach the basics of diabetes care in order to improve treatment for those living with diabetes in underserved areas.